SS-31 (Elamipretide): The Mitochondria-Targeting Peptide

SS-31 was originally developed by Hazel Szeto at Cornell University Medical College in the early 2000s. The peptide is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) designed with a specific structural motif that allows it to pass through cell membranes and accumulate in the inner mitochondrial membrane at concentrations up to 1,000-fold compared to its concentration in the cytoplasm. The compound was licensed to Stealth BioTherapeutics, which developed it under the names Bendavia and later elamipretide. Stealth advanced elamipretide through multiple clinical programs targeting conditions driven by mitochondrial dysfunction, including Barth syndrome, primary mitochondrial myopathy, heart failure with preserved ejection fraction (HFpEF), and dry age-related macular degeneration (dry AMD). In September 2025, the FDA granted accelerated approval for elamipretide under the brand name FORZINITY. It is the first FDA-approved mitochondria-targeted therapeutic and the first approved treatment for Barth syndrome, a rare genetic disorder caused by mutations in the tafazzin gene that lead to abnormal cardiolipin metabolism.

Cardiolipin is a phospholipid found almost exclusively in the inner mitochondrial membrane. It plays a structural role in maintaining the cristae architecture of the membrane and a functional role in supporting the electron transport chain complexes, particularly complexes III and IV. When cardiolipin becomes oxidized or depleted, mitochondrial function deteriorates. Electron transport becomes less efficient, ATP production drops, and reactive oxygen species (ROS) generation increases, creating a cycle of oxidative damage. SS-31 binds selectively and reversibly to cardiolipin. This binding normalizes the structure of the inner mitochondrial membrane, stabilizes the electron transport chain supercomplexes, and improves the efficiency of oxidative phosphorylation. The net result is increased ATP production and reduced ROS output. Unlike conventional antioxidants that scavenge ROS after they are produced, SS-31 acts at the source of mitochondrial ROS generation. SS-31 also has effects beyond the mitochondria. Preclinical studies show it reduces inflammation by inhibiting the NLRP3 inflammasome and decreasing pyroptosis, a form of inflammatory cell death. It has been shown to promote mitochondrial biogenesis and improve mitochondrial dynamics (the balance between fission and fusion), both of which decline with aging.

In preclinical models, SS-31 has shown benefits across a wide range of age-related conditions. In models of cognitive impairment, it improved cognitive function by promoting mitochondrial and synaptic health. In cardiac models, it restored mitochondrial function in failing hearts. In skeletal muscle models, it reversed age-related declines in muscle function by improving mitochondrial bioenergetics. Clinical trial results have been mixed. Two phase 3 trials for primary mitochondrial myopathy (MMPOWER-3) and Barth syndrome (TAZPOWER) had different outcomes. The MMPOWER-3 trial did not meet its primary endpoint. However, the TAZPOWER trial supported the accelerated approval for Barth syndrome based on improvements in the six-minute walk distance, a measure of muscle strength and endurance. For heart failure, the phase 2/3 RELAX-HF trial in HFpEF did not meet its primary endpoint, though secondary analyses suggested benefit in specific patient subgroups. Stealth BioTherapeutics continues to evaluate elamipretide in additional cardiac indications. A second-generation mitochondria-targeted compound, bevemipretide (SBT-272), is being evaluated for ALS and other rare neurological conditions. Intravenous dosing in clinical trials has ranged from 0.01 mg/kg/hour to 0.25 mg/kg/hour over four hours. In the research peptide community, SS-31 is typically used at doses between 10 and 50 mg per day via subcutaneous injection, though standardized protocols do not exist outside of clinical trials.

A user on r/Peptides who used SS-31 for eight weeks described it as a subtle but meaningful shift: “I didn't feel anything dramatic the first week. By week three, my endurance during workouts improved noticeably. I was recovering faster between sets and my resting heart rate was lower. By week six I felt like I had more energy across the board, not a stimulant energy, more like my cells were just working better.“ A user on r/Biohackers shared: “I ran SS-31 at 20 mg daily for a month as part of an anti-aging stack. The most noticeable change was in my mental clarity during the afternoon. That 2pm brain fog I had been fighting for years just disappeared. Sleep also improved, which I wasn't expecting.“ Another user noted that the effects seemed to build over several weeks rather than being immediately apparent.

• Improved physical endurance and reduced exercise-related fatigue
• Faster recovery between training sessions
• Reduced mental fatigue, especially during afternoon energy dips
• Better overall energy levels without stimulation or jitteriness
• Improved recovery from periods of high physical or metabolic stress
• Potential improvement in sleep quality

SS-31 addresses mitochondrial function, so it pairs naturally with peptides that work through other mechanisms of cellular repair and regeneration. Epithalon (Epitalon), a telomerase activator, is a common longevity stack pairing. SS-31 improves the energy-producing capacity of existing mitochondria while Epithalon addresses cellular aging at the chromosomal level. BPC-157 is another useful pairing. While SS-31 focuses on mitochondrial bioenergetics, BPC-157 supports tissue healing through growth factor modulation and angiogenesis. Together they provide broad cellular and tissue support. For cognitive-focused stacking, Semax pairs well with SS-31. Semax enhances BDNF and neuroplasticity, while SS-31 supports the mitochondrial function that neurons depend on for sustained high performance. This combination is gaining interest among people targeting age-related cognitive decline.